DESCRIPTION
This is held bi-weekly Monday at Noon, as well as weekly on Fridays at 7:30 a.m.

These are weekly meetings done for the disease group members. During this meeting, we discuss patients, journal articles, and clinical trial protocols. We also develop treatment guidelines during the meeting. There are 6 meetings a month.  This committee continually brings forth new information from patient care, research, and education to the group for consideration and discussion of implementation to improve our practices.  

TARGET AUDIENCE
MD, Resident/Fellows, APP/NP, Nursing, Pharmacists, Social workers, students

LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

• Describe how to utilize the appropriate measures to risk-stratify patients with plasma cell disorders.
• Explain the best use of various testing strategies to make the right diagnosis of plasma cell disorders.
• Define the treatment approaches that lead to the best outcomes for patients with plasma cell disorders.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA
The Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure Summary
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies:

Shaji Kumar, M.D. 
Research/Grant support - Abbvie, Amgen, Allogene, Astra-Zeneca, BMS, Carsgen,  GSK, Janssen,  Novartis, Roche-Genentech, Takeda, Regeneron.
Consulting - Oncopeptides, Beigene, Antengene

Prashant Kapoor, M.D. 
Research/Grant support - AbbVie, Takeda, Sanofi, Janssen, Karyopharm, Glaxo SmithKlein, Regeneraon, Ichnos Sciences, and Amgen.
Consulting - Pharmacyclics, BeiGene, Cellectar, Oncopeptides, X4 Pharmaceuticals, Kite, GSK, and Karyopharm.

All relevant financial relationships listed for these individuals have been mitigated.